Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences (ANIX) received its first Australian composition-of-matter patent for its breast cancer vaccine technology, providing exclusive protection in Australia through 2040. The patent, issued by IP Australia as Patent Number 2020221280 and titled “Vaccine Adjuvants and Formulations,” covers a vaccine approach exclusively licensed from Cleveland Clinic.
The Australian patent complements Anixa’s existing portfolio in the United States and other markets including Europe, China and Japan, broadening its global intellectual property estate. A completed Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, met all major primary endpoints, showed the vaccine was safe and well tolerated, and produced protocol-defined immune responses in more than 74% of participants, supporting further clinical development.
Anixa Biosciences (ANIX) appointed Carmen Guerra, M.D., M.S.C.E., F.A.C.P., of the University of Pennsylvania, to its Cancer Business Advisory Board.
The company said it expects Dr. Guerra’s expertise to support advancement of its breast cancer vaccine toward a planned Phase 2 trial and its ongoing Phase 1 ovarian cancer CAR-T therapy trial. Dr. Guerra is a Professor of Medicine and of Biostatistics and Epidemiology at the Perelman School of Medicine and Associate Director of Community Outreach and Engagement at the Abramson Cancer Center.
Her research focuses on increasing participation in cancer screening and clinical trials, and she leads several Penn Medicine cancer screening programs. She also plays key roles in NCI-funded HPV prevention research and in developing American Cancer Society clinical practice guidelines.
Anixa Biosciences (ANIX) will feature its Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, in an interview on the RedChip Small Stocks, Big Money™ show airing on Bloomberg TV on Saturday, September 12, at 7:00 PM ET.
Dr. Kumar will discuss recently announced successes in cancer vaccine development and Anixa’s breast cancer vaccine, which the company expects could be used to treat cancer, prevent recurrence, and potentially reduce the risk of developing breast cancer. Steinberg, a breast cancer survivor who participated in Anixa’s Phase 1 clinical trial, will share her cancer journey and experience receiving the vaccine. Bloomberg TV reaches an estimated 73 million U.S. homes, and the segment will also be available online at a specified YouTube link.
Anixa Biosciences (ANIX) will present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026, at Nasdaq’s San Francisco headquarters.
Chairman and CEO Dr. Amit Kumar will speak at 3:40 PM PT, followed by a breakout session. The presentation will cover updates on Anixa’s two clinical programs: a CAR-T therapy for recurrent and resistant ovarian cancer in an ongoing Phase 1 trial with Moffitt Cancer Center, and a therapeutic and prophylactic breast cancer vaccine whose Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, met all primary endpoints. Dr. Kumar will also outline future plans for a Phase 2 vaccine trial and place the program in context with recent positive melanoma vaccine data.
Anixa Biosciences (NASDAQ: ANIX) will present at the 2026 Cantor Fitzgerald Global Healthcare Conference in New York on September 11, 2026, at 8:00 AM ET. President, COO & CFO Mike Catelani will review its breast cancer vaccine, which completed a Phase 1 trial funded by the U.S. Department of Defense, meeting all primary endpoints, including safety, and generating protocol-defined immune responses in 74% of participants. Preparations are underway for Phase 2. He will also discuss the ovarian cancer CAR-T therapy lira-cel, now at the fifth and highest dose cohort with lymphodepletion, where no dose-limiting toxicities have been observed and four patients have surpassed one year of survival, the longest at about 28 months.
Anixa Biosciences (NASDAQ: ANIX) will present at the H.C. Wainwright 28th Annual Global Investment Conference, with a webcast available starting 7:00 AM ET on September 11, 2026, ahead of the conference dates of September 14–16, 2026.
According to Anixa, the presentation by Chairman and CEO Dr. Amit Kumar will review the company’s breast cancer vaccine, which completed a Phase 1 trial meeting all primary endpoints, including safety, with protocol-defined immune responses in 74% of participants, and for which Phase 2 preparations are underway. Dr. Kumar will also discuss the ovarian cancer CAR-T therapy lira-cel, now at the fifth and highest dose cohort evaluated to date with lymphodepletion introduced, where no dose-limiting toxicities have been observed and four patients have surpassed one year of survival, the longest at approximately 28 months.
Anixa Biosciences (NASDAQ: ANIX) reported that IP Australia issued a Notice of Acceptance for a patent covering its breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. Titled “Vaccine Adjuvants and Formulations,” the patent protects Anixa’s preventive and therapeutic breast cancer vaccine approach in Australia.
The patent complements existing coverage in the United States, Europe, China, Japan and other regions, expanding Anixa’s global intellectual property estate. A recently completed Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, met major primary endpoints, showed safety and tolerability, and generated protocol-defined immune responses in over 74% of participants.
Anixa Biosciences (NASDAQ: ANIX) reported treatment of the first patient in cohort 5 of its Phase 1 FSHR-targeted CAR-T/CER-T trial for recurrent ovarian cancer at Moffitt Cancer Center.
The study has escalated to 1×10⁷ CAR-positive cells/kg, with no dose-limiting toxicities observed to date and five patients surviving 13–28 months post-treatment.
Anixa Biosciences (NASDAQ: ANIX) received its first Korean composition-of-matter patent (No. 10-2960889) for its breast cancer vaccine, granting exclusive protection in South Korea through 2040.
The patent, licensed from Cleveland Clinic, extends Anixa’s global IP estate and supports ongoing U.S. clinical development after a Phase 1 trial showed immune responses in 74% of participants.
Anixa Biosciences (NASDAQ: ANIX) reported updated clinical data for its breast cancer vaccine and ovarian cancer CAR‑T therapy presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium.
The completed Phase 1 breast cancer vaccine trial met all major primary endpoints, showed the vaccine was safe and well tolerated at the maximum tolerated dose, and induced protocol-defined immune responses in 74% of participants. The ongoing Phase 1 trial of ovarian cancer CAR‑T therapy lira-cel reported survival observations of multiple patients living over one year after treatment. Both programs are being developed with Cleveland Clinic and Moffitt Cancer Center, and presentations are available on Anixa's investor events webpage.